Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.

Expert opinion on drug metabolism & toxicology - 1 Jul 2026

Abdy Elaria, Betancourt Jean-Pierre, Kar Supratik

Abstract excerpt

INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common subtype, yet resistance to therapy remains a major clinical challenge. Up to 40% of patients carry PIK3CA mutations that activate PI3K/AKT/mTOR signaling and drive relapse, highlighting the need for more selective and tolerable targeted therapies. AREAS COVERED: This review...

Topics

Join the communities discussing this publication.

Antineoplastic Agents
Class I Phosphatidylinositol 3-Kinases
Drug Resistance, Neoplasm
Erb-b2 Receptor Tyrosine Kinases
Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phosphoinositide-3 Kinase Inhibitors

Progression-Free Survival

Source

Identifiers

PMID: 42496151
DOI: 10.1080/17425255.2026.2710110

Genes

PIK3CA
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.PMID 42496151Read ↗

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read ↗

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read ↗

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Semantic proximity Read ↗

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Efficacy of PI3K inhibitors in advanced breast cancer.Semantic proximity Read ↗

Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.Semantic proximity Read ↗

Targeting PIK3CA Alterations in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: New Therapeutic Approaches and Practical Considerations.Semantic proximity Read ↗

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.